A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Clinical trial NCT04007588 · WITHDRAWN
Trial details
- NCT number
- NCT04007588
- Sponsor
- Dana-Farber Cancer Institute
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-06
- Primary completion
- 2019-12-19
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.